Navigation Links
Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011

SUNNYVALE, Calif., Jan. 14, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that it will report results for its second quarter of fiscal 2011, ended December  31, 2010 on Thursday, January 27, 2011 after the market closes.

A conference call to review the results will begin at 2:00 p.m. PT/5:00 p.m. ET and will be hosted by Euan S. Thomson, Ph.D., president and chief executive officer and Derek Bertocci, senior vice president and chief financial officer.

The conference call dial-in numbers are 1-866-578-5747 (USA) or 1-617-213-8054 (International), Conference ID: 81349716. In addition, a dial-up replay of the conference call will be available beginning January 27, 2011 at 5:00 p.m. PT/8:00 p.m. ET and ending on February 3, 2011. The replay telephone number is 1-888-286-8010 (USA) or 1-617-801-6888 (International), Conference ID:  44779168.

A live webcast of the call will also be available from the Investor Relations section of the corporate Web site at  A webcast replay can be accessed on the corporate Web site beginning Thursday, January 27, 2011 at approximately 5:00 p.m. PT/8:00 p.m. ET. The replay will remain available until Accuray announces its results for the third quarter of fiscal 2011, ending March 31, 2011.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 215 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit

SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008
2. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO
3. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
4. Accuray Reschedules Announcement of Results for First Quarter of Fiscal 2009
5. Accuray Postpones Release of First Quarter Fiscal 2009 Results
6. Accuray Achieves Milestone of 150th CyberKnife System Installed Worldwide
7. Accuray Incorporateds CEO to Speak at 27th Annual JP Morgan Healthcare Conference
8. Accuray Incorporated to Report Second Quarter Fiscal Year 2009 Financial Results
9. 10 Percent of U.S. Installed Base Signs on to Use Accuray Treatment Planning Service
10. Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference
11. Accuray Incorporated to Present at Robert Baird 2009 Healthcare Conference
Post Your Comments:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):